11 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 11 Phase 3, 4 Phase 1, 4 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 8, Terminated 2, Active not recruiting 1 |
| Phase 1 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
| Phase 4 | 2 | Completed 1, Recruiting 1 |
Follow deutetrabenazine: new trials by email Literature Review of deutetrabenazine trials Research Report on deutetrabenazine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities Deutetrabenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Recruiting | University Hospitals Cleveland Medical Center | 25 | 2026-06-22 | 2026-07-06 |
| Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China Deutetrabenazine - Huntington's Disease, Chorea | Phase 4 | Completed | Teva Branded Pharmaceutical Products R&D LLC | 50 | 2024-02-02 | 2026-08-27 |
| Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated with HD Deutetrabenazine Oral Tablet [Austedo], Placebo oral tablet - Huntington Disease | Phase 1 | Terminated | Fundacion Huntington Puerto Rico | 36 | 2022-01-21 | 2025-02-27 |
| Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease Deutetrabenazine - Huntington Disease | Phase 2 / Phase 3 | Active not recruiting | Vanderbilt University Medical Center | 30 | 2021-11-19 | 2026-08-05 |
| An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia Deutetrabenazine 6 MG - Dystonia, Primary | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 15 | 2021-04-29 | 2024-09-20 |
| Symptomatic Therapy for Patients With Huntington's Disease Haloperidol 2Mg Tab, Risperidone 1Mg Tab, Zoloft 50Mg Tablet - Huntington Disease | Phase 1 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 60 | 2020-03-12 | 2021-04-02 |
| A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy TEV-50717 - Cerebral Palsy, Dyskinetic | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 44 | 2020-02-04 | 2024-04-22 |
| A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents TEV-50717, Placebo - Cerebral Palsy, Dyskinetic | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 63 | 2019-08-06 | 2023-09-08 |
| A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS) TEV-50717, Placebo - Tourette Syndrome | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 158 | 2018-05-31 | 2021-11-09 |
| Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents TEV-50717, Placebo - Tourette Syndrome | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 228 | 2018-05-25 | 2021-11-09 |
| Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents TEV-50717, Placebo - Tourette Syndrome | Phase 2 / Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 119 | 2018-02-05 | 2021-11-09 |
| Addressing Involuntary Movements in Tardive Dyskinesia SD-809, Placebo - Tardive Dyskinesia | Phase 3 | Completed | Auspex Pharmaceuticals, Inc. | 298 | 2014-10-31 | 2026-06-23 |
| Reducing Involuntary Movements in Participants With Tardive Dyskinesia SD-809, Placebo - Tardive Dyskinesia | Phase 3 | Completed | Auspex Pharmaceuticals, Inc. | 343 | 2014-10-20 | 2022-04-01 |
| A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS) SD-809 - TOURETTE SYNDROME | Phase 1 | Completed | Auspex Pharmaceuticals, Inc. | 23 | 2014-07-01 | 2021-11-09 |
| Aim to Reduce Movements in Tardive Dyskinesia SD-809, Placebo - Tardive Dyskinesia | Phase 2 / Phase 3 | Completed | Auspex Pharmaceuticals, Inc. | 117 | 2014-06-01 | 2021-11-09 |
| Alternatives for Reducing Chorea in Huntington Disease SD-809 - Chorea Associated With Huntington Disease | Phase 3 | Completed | Auspex Pharmaceuticals, Inc. | 119 | 2013-11-12 | 2021-11-09 |
| First Time Use of SD-809 in Huntington Disease SD-809, Placebo - Chorea | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 90 | 2013-08-05 | 2017-09-20 |
Huntington Disease (6) · Movement Disorders (4) · Tardive Dyskinesia (4) · Tourette Syndrome (4) · Central Nervous System Diseases (3) · Chorea (3) · Dyskinesias (3) · Nervous System Diseases (3) · Neurologic Manifestations (3) · Signs and Symptoms (3) · Cerebral Palsy (2) · Caregiver Burden (1) · Developmental Disabilities (1) · Dystonic Disorders (1) · Intellectual Disability (1)
Teva Branded Pharmaceutical Products R&D, Inc. (6) · Auspex Pharmaceuticals, Inc. (5) · Fundacion Huntington Puerto Rico (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Teva Branded Pharmaceutical Products R&D LLC (1) · University Hospitals Cleveland Medical Center (1) · University of Pennsylvania (1) · Vanderbilt University Medical Center (1)
United States (14) · Poland (7) · Canada (5) · Australia (4) · Denmark (4) · Hungary (4) · Italy (4) · Russia (4) · Slovakia (4) · Spain (4) · Ukraine (4) · Czechia (3) · Argentina (2) · China (2) · Colombia (2)
Amy E Brown, MD (1) · Stephen Ruedrich, MD (1) · Zhi-Ying Wu (1)
PMID 38557959, PMID 39825184, PMID 27380342, PMID 28265459, PMID 28668671, PMID 29480210, PMID 31296586, PMID 34609495, PMID 34661664, PMID 36242718
2014 (2), 2016 (2), 2017 (1), 2018 (1), 2019 (1)